Allogeneic, off-the-shelf, SARS-CoV-2-specific T cells (ALVR109) for the treatment of COVID-19 in high-risk patients

Defects in T-cell immunity to SARS-CoV-2 have been linked to an increased risk of severe COVID-19 (even after vaccination), persistent viral shedding and the emergence of more virulent viral variants. To address this T-cell deficit, we sought to prepare and cryopreserve banks of virus-specific T cel...

Descripción completa

Detalles Bibliográficos
Autores principales: Vasileiou, Spyridoula, Hill, LaQuisa, Kuvalekar, Manik, Workineh, Aster G., Watanabe, Ayumi, Velazquez, Yovana, Lulla, Suhasini, Mooney, Kimberly, Lapteva, Natalia, Grilley, Bambi J., Heslop, Helen E., Rooney, Cliona M., Brenner, Malcolm K., Eagar, Todd N., Carrum, George, Grimes, Kevin A., Leen, Ann M., Lulla, Premal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Article - Cell Therapy & Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316279/
https://www.ncbi.nlm.nih.gov/pubmed/36373249
http://dx.doi.org/10.3324/haematol.2022.281946

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316279/
https://www.ncbi.nlm.nih.gov/pubmed/36373249
http://dx.doi.org/10.3324/haematol.2022.281946

Ejemplares similares